Viper Resources Announces Acquistion of ImuMed Deutschland.

VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 11, 1999--

Viper Resources, Inc. (OTC BB:VPRS), an Arizona corporation ("Viper"), has acquired ImuMed Deutschland GmbH, a German biotech and pharmaceutical manufacturing group (the "ImuMed Group"), from Transplant Technologies, Inc., a Minnesota Corporation.

The ImuMed Group was acquired in settlement of a loan from Viper to Transplant Technologies in the approximate amount of US$700,000 and the receipt by Viper of a US$350,000 promissory note from Transplant Technologies due in three years and requiring mandatory prepayments by the borrower in certain circumstances. The ImuMed Group had revenues in 1998 of approximately US$2.1 million and an EBITDA(a) of approximately US$513,000. The ImuMed Group consists of two operating subsidiaries Antitoxin GmbH and IFI GmbH and Co. KG based in Meckesheim near Heidelberg that manufacture a range of blood grouping tests and other serology products. The ImuMed Group owns its facilities, additional property and associated land.

Viper Resources, Inc. will be moving its corporate domicile to Bermuda and will be seeking shareholder approval to merge with a Bermuda corporation newly formed for this purpose. The surviving corporation of the merger will be named ImuMed International Inc.

The intent of Viper Resources, Inc. is to expand the core business of ImuMed Deutschland GmbH by organic growth and seek other acquisitions in the biotech and pharmaceutical industry.

Eric F. Kohn, TD(b), was elected to the Board of Directors of Viper Resources, Inc. on July 28, 1999 and was also appointed Chairman, President and CEO.

Dr. Ortwin Walla(b) is the Geschaftsfuhrer (President) of ImuMed Deutschland GmbH and its subsidiaries.

ERIC F KOHN , TD, BSc, FCIM, FIMgt, a UK citizen, has had thirty years of experience in industrial marketing, manufacturing and management in Europe and the United States. In 1972, he founded a group of West German companies that manufactured industrial positioning systems with factories in Los Angeles and Munich. In 1983, Mr. Kohn sold this group of companies to a US public company and remained Chairman until 1985. He then joined Bankers Trust where he was responsible for Corporate Finance in Switzerland, Germany and Italy until 1987. In November 1987, Mr. Kohn founded Barons Financial Services, a corporate finance advisory services company based in Geneva and London that specializes in Mergers and Acquisitions, Private Placements and general cross-border advisory Investment Banking, and has served as the Managing Director of Barons since its inception. Mr. Kohn also currently serves as Chairman of Omninet International Ltd, a Bermuda Company seeking investments.

In September 1991, he was elected Chief Executive Officer and Vice Chairman of Holmes Protection Group, Inc., a Delaware corporation listed on the London Stock Exchange, which had defaulted on approximately $70 million of debt to seven North American institutions. In this position, Mr. Kohn led the restructuring including the implementation of a new business strategy, conservative accounting policies and elimination of substantially all debt. The restructuring was completed in August, 1992 and resulted in taking the company from $27 million of negative shareholders' funds to $42 million of positive shareholders' funds. He resigned as Chief Executive Officer in May 1993 and remained a Director until July 1994.

Mr. Kohn was educated at the University of Glasgow and is a Fellow of the British Institute of Management and the Institute of Marketing. Mr. Kohn is a Reserve Army Officer in the British Army with the rank of Lieutenant Colonel and holds the Territorial Decoration. He is fluent in English, French and German.

Dr. ORTWIN WALLA, an Austrian Citizen, is an accomplished scientist with 13 years of experience in the area of production and quality control of polyclonal and monoclonal immune sera for therapeutic and diagnostic use. From 1982 to 1987, he attended the Leopold-Franzens-University in Innsbruck, Austria, and pursued advanced studies in biology at the Max Planck Institute for cell biology in Ladenburg, Germany, in cooperation with the Institute of Biochemistry at the University of Innsbruck and was awarded his Magister in 1987 and his Doctorate in 1990.

In February 1991, Dr. Walla was employed by Antitoxin Dr. Helmbold GmbH ("Antitoxin") and has held a number of management positions for Antitoxin and its affiliated companies. He was appointed Head of Quality Control in December 1991, Managing Director in 1996 and Head of Production in 1999. Dr. Walla also contemporaneously served as Head of Quality Control for immune sera at Knoll AG/Ludwigshafen since 1991, becoming Head of Production for this company in May 1999. From August 1994 until February 1998 Dr. Walla also served as Head of Quality Control at FBM-Pharma GmbH, Ludwigshafen, Germany.

In July 1999, Dr. Walla was appointed as Geschaftsfuhrer (Managing Director) of ImuMed Deutschland GmbH, which acquired Antitoxin and its affiliated companies and the associated land and buildings from the estate Dr. Hembold, the founder of Antitoxin.

Statements made in this press release that are NOT historical or current facts are "forward looking statements" made pursuant to the safe harbor provisions of federal securities laws. Forward looking statements represent management's best judgment as to what may occur in the future, but are subject to certain risks and uncertainties that could cause actual results and events to differ materially from those presently anticipated or projected.

(a) on an Unaudited Proforma Basis reflecting operations under the current ownership structure

(b) Resumes are attached